AbbVie Inc. (ABBV)

65.97
NYSE : Health Technology
Prev Close 67.52
Day Low/High 65.48 / 67.79
52 Wk Low/High 62.66 / 98.70
Avg Volume 10.28M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 99.83B
EPS 3.70
P/E Ratio 24.03
Div & Yield 4.28 (6.17%)

Jim's Daily Rundown

Jim discusses Honeywell and Abbott Labs earnings as well as Broadcom and the oils.

Dollar Traders Believe What They See, Not What They Hear: Market Recon

Dollar Traders Believe What They See, Not What They Hear: Market Recon

Currency traders see the Trump administration boosting manufacturing via a weak dollar.

Jim's Daily Rundown

Jim discusses GE, Comcast, Illinois Tool Works, and Abbott Labs, all of which reported earnings Wednesday morning.

Jim's Daily Rundown

In today's video, Jim discusses the government shutdown, an Eli Lilly downgrade, Schlumberger after Friday's earnings, and several other market-related topics.

Jim Cramer: The 3 Best Sectors That Lifted the Stock Market

Jim Cramer: The 3 Best Sectors That Lifted the Stock Market

It's hard to understand the magnitude of the change.

AbbVie Becomes #133 Most Shorted S&P 500 Component, Replacing Equity Residential

AbbVie Becomes #133 Most Shorted S&P 500 Component, Replacing Equity Residential

The most recent short interest data has been released for the 12/29/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Deere & Co., Analog Devices, Mercadolibre: 'Mad Money' Lightning Round

Deere & Co., Analog Devices, Mercadolibre: 'Mad Money' Lightning Round

Jim Cramer is bullish on Deere & Co., Analog Devices, Mercadolibre, Teradyne, AbbVie, Antero Midstream Partners.

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

From global growth and bonds to index funds, Jim Cramer explains why stocks keep going up, giving the Dow and Nasdaq their best start to the new year since 2006.

Blizzard Pounds New York, Boston as 'Bomb Cyclone' Cripples East Coast Airports

Blizzard Pounds New York, Boston as 'Bomb Cyclone' Cripples East Coast Airports

A 'Bomb Cyclone' snowstorm could dump as much as 18 inches on New York and Boston Thursday, the National Weather Service has warned, as the Atlantic coast faces yet another extreme weather battering.

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

GOP Tax Fix Could Zero Out Orphan Drug Tax Credit

GOP Tax Fix Could Zero Out Orphan Drug Tax Credit

The hotly debated tax reform championed by the Trump White House needs to be paid for by spending cuts. One proposed change could eliminate the tax credit for companies developing treatments through the Orphan Drug Act.

Miles White of Abbott Labs: Cramer's Top Takeaways

Miles White of Abbott Labs: Cramer's Top Takeaways

Jim Cramer spotlights Abbott Laboratories CEO Miles White for his value-creating success.

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Jim Cramer says don't be too quick to ascribe today's gains just to tax reform. This rally was roaring well before that. Instead, credit Cisco and Wal-Mart Stores.

FDA Approves AstraZeneca's Blood Cancer Drug

FDA Approves AstraZeneca's Blood Cancer Drug

With newly approved Calquence in hand, AstraZenca is set to compete against J&J-AbbVie's Inbruvica first on mantle cell lymphoma but down the road the challenge could be on more common blood cancers.

Allergan: How to Deal with an Emotional Position Unemotionally

When the market is completely against a stock, it is important to go back through the numbers and figure out what the company is worth.

Washington Uncertainty and a Healthcare Selloff Send Stocks Lower

Washington Uncertainty and a Healthcare Selloff Send Stocks Lower

Uncertainty in Washington, D.C., a healthcare sector in selloff mode and a big deals day on Wall Street sent U.S. equities lower to begin the week.

Stocks Burrow Further Into the Red on Logistics of Tax Cut Plan

Stocks Burrow Further Into the Red on Logistics of Tax Cut Plan

Stocks dig further into the red on Monday, Oct. 30, as investors weigh how a proposed phase-in corporate tax rate cut might impact U.S. companies.

Merck Weighs on Dow but Apple and Tech Rally Give Lift to Nasdaq

Merck Weighs on Dow but Apple and Tech Rally Give Lift to Nasdaq

Stocks are mixed on Monday as Mueller's Russia investigation takes its first concrete steps.

Stop Worrying About Valuations After Amazon, Alphabet and Microsoft's Earnings

Stop Worrying About Valuations After Amazon, Alphabet and Microsoft's Earnings

The revenue and profit gains from some of the biggest technology companies like Amazon AMZN, Alphabet GOOGL and Microsoft MSFT show that valuations aren't so stretched.

Google, Amazon, Aetna and Exxon - 5 Things You Must Know Before the Market Opens

Google, Amazon, Aetna and Exxon - 5 Things You Must Know Before the Market Opens

U.S. stock futures are rising on Friday, and the tech-heavy Nasdaq index is poised for sharp opening gains after Amazon.com, Alphabet, Microsoft and Intel issue powerful earnings reports.

There Is Sound Fundamental Reasoning Behind the Positivity: Market Recon

There Is Sound Fundamental Reasoning Behind the Positivity: Market Recon

The ECB's super dovish message was good for the markets.

Alphabet, Amazon and Expedia: This Is What You Must Know on Friday

Alphabet, Amazon and Expedia: This Is What You Must Know on Friday

U.S. futures point a higher open following earnings beats from Amazon, Alphabet and Microsoft after the bell on Thursday.

Futures and Dollar Rise as Trump Narrows Down Pool for Next Fed Chair

Futures and Dollar Rise as Trump Narrows Down Pool for Next Fed Chair

A decision should be made 'in the coming days.'

Third-Quarter U.S. Economic Growth to Reveal Hurricane Damage in Week Ahead

Third-Quarter U.S. Economic Growth to Reveal Hurricane Damage in Week Ahead

A string of severe hurricanes that swept across the south and southeastern portions of the U.S. and Puerto Rico toward the end of the third quarter could put a big dent in economic growth.

Get Ready for an Earnings Onslaught: Cramer's 'Mad Money' Recap (Friday 10/20/17)

Get Ready for an Earnings Onslaught: Cramer's 'Mad Money' Recap (Friday 10/20/17)

Jim Cramer's game plan is jam-packed for next week; this is the heart of earnings season.

UnitedHealth and a Bipartisan Healthcare Deal Send Dow, S&P 500 to Records

UnitedHealth and a Bipartisan Healthcare Deal Send Dow, S&P 500 to Records

A flood of earnings from the likes of UnitedHealth, Johnson & Johnson and Goldman Sachs keeps investors occupied on Tuesday.

Healthcare Drives Small Gains for Dow While Rest of Market Slips

Healthcare Drives Small Gains for Dow While Rest of Market Slips

A flood of earnings from the likes of UnitedHealth, Johnson & Johnson and Goldman Sachs keeps investors occupied on Tuesday.

UnitedHealth and Johnson & Johnson Lead Bruised Healthcare Sector to Gains

UnitedHealth and Johnson & Johnson Lead Bruised Healthcare Sector to Gains

Earnings beats from UnitedHealth Group Inc. and Johnson & Johnson led the healthcare sector to recover from a days-long presidential beating.

Las Vegas Shooting Holds Headlines While Stocks Jump to New Records

Las Vegas Shooting Holds Headlines While Stocks Jump to New Records

Stocks look past the worst mass shooting in U.S. history on Monday, Oct. 2, to trade at new records.

Stocks Trade at Records Again Even as Las Vegas Shooting Death Toll Rises

Stocks Trade at Records Again Even as Las Vegas Shooting Death Toll Rises

Stocks look past the worst gun shooting in U.S. history on Monday, Oct. 2, to trade at new records.

TheStreet Quant Rating: B- (Buy)